CVI Pharmaceuticals Overview
- Year Founded
-
2007
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.63M
- Investors
-
3
CVI Pharmaceuticals General Information
Description
Developer of small-molecule oral therapies intended to aid in the treatment of cardiovascular and metabolic diseases such as hypercholesterolemia, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), obesity, and other rare metabolic diseases. The company's main product chemistry class 1 oral small-molecule lipid-lowering drug CVI-LM001 has been tested in vivo and in vitro, enabling patients to get treatment without any side effects.
Contact Information
Website
cvipharma.comCorporate Office
- 898 Ha Lei Road, Building 1, Suite 304, Zhang
- Jiang High Tech Park, Pudong New District
- Shanghai, 201203
- China
Corporate Office
- 898 Ha Lei Road, Building 1, Suite 304, Zhang
- Jiang High Tech Park, Pudong New District
- Shanghai, 201203
- China
CVI Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 21-Jul-2021 | $4.63M | Completed | Clinical Trials - Phase 2 | ||
| 4. Secondary Transaction - Private | 26-Feb-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | 16-Jun-2016 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC | 25-Nov-2013 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 31-Dec-2007 | Completed | Startup |
CVI Pharmaceuticals Patents
CVI Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022048620-A1 | Polymorphs of crystalline forms of 3, 10-dimethoxy-5, 8, 13, 13a-tetrahydro-6h-isoquinolino [3, 2-a] isoquinolin-9-yl 3-fluorobenzenesulfonate and salts thereof | Inactive | 03-Sep-2020 | ||
| US-20230279002-A1 | Polymorphs of crystalline forms of 3,10-dimethoxy-5,8,13,13a-tetrahydro-6h-isoquinolino[3,2-a]isoquinolin-9-yl 3-fluorobenzenesulfonate and salts thereof | Inactive | 03-Sep-2020 | ||
| US-20220387403-A1 | Compounds, compositions and methods for treating nash, nafld, and obesity | Inactive | 01-Oct-2019 | ||
| WO-2021067490-A1 | Compounds, compositions and methods for treating nash, nafld, and obesity | Inactive | 01-Oct-2019 | ||
| US-20110009628-A1 | Compounds and compositions for modulating lipid levels and methods of preparing same | Inactive | 08-Jul-2009 | C07D471/04 |
CVI Pharmaceuticals Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Wuhan Haite Biopharmaceutical | Corporation | Minority | ||
| BVCF | Venture Capital | Minority | ||
| 5Y Capital | Venture Capital | Minority |
CVI Pharmaceuticals FAQs
-
When was CVI Pharmaceuticals founded?
CVI Pharmaceuticals was founded in 2007.
-
Where is CVI Pharmaceuticals headquartered?
CVI Pharmaceuticals is headquartered in Shanghai, China.
-
What industry is CVI Pharmaceuticals in?
CVI Pharmaceuticals’s primary industry is Drug Discovery.
-
Is CVI Pharmaceuticals a private or public company?
CVI Pharmaceuticals is a Private company.
-
What is the current valuation of CVI Pharmaceuticals?
The current valuation of CVI Pharmaceuticals is .
-
What is CVI Pharmaceuticals’s current revenue?
The current revenue for CVI Pharmaceuticals is .
-
How much funding has CVI Pharmaceuticals raised over time?
CVI Pharmaceuticals has raised $4.63M.
-
Who are CVI Pharmaceuticals’s investors?
Wuhan Haite Biopharmaceutical, BVCF, and 5Y Capital have invested in CVI Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process